WO1996006604B1 - Methods for identifying and treating resistant tumors - Google Patents
Methods for identifying and treating resistant tumorsInfo
- Publication number
- WO1996006604B1 WO1996006604B1 PCT/US1995/011125 US9511125W WO9606604B1 WO 1996006604 B1 WO1996006604 B1 WO 1996006604B1 US 9511125 W US9511125 W US 9511125W WO 9606604 B1 WO9606604 B1 WO 9606604B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mrp
- use according
- pages
- compound
- protein
- Prior art date
Links
Abstract
This invention provides a method of identifying and reversing multidrug resistance in a multidrug resistance tumor comprising administering a multidrug resistance reversing amount of any of the compounds as defined herein.
Claims
-79-
AMENDED CLAIMS
[received by the International Bureau on 9 May 1996 (09.05.96); original claims 16-18 amended; remaining claims unchanged (2 pages)]
10. The use of Claim 3 employing the compound 8- propyl-7-[3-[4-acetyl-3-methoxy-2-propylphenoxy]propoxy]- 3,4-dihydro-2H-l-benzopyran-2-carboxylic acid or a pharmaceutically acceptable base addition salt or solvate thereof.
11. The use of Claim 6 employing the compound 2-[2- propyl-3-[4-[2-ethyl-5-hydroxy-4-(4-fluorophenyl)- phenoxy] utoxy]phenoxy]benzoic acid or a pharmaceutically acceptable base addition salt or solvate thereof.
12. The use of Claim 2 employing the compound 2-[2-
(phenylmethyl)-3-[3-[2-ethyl-5-hydroxy-4-(4-fluorophenyl)- phenoxyjpropoxy]phenoxy]benzoic acid or a pharmaceutically acceptable base addition salt or solvate thereof.
13. Use of amphiphilic anions having a molecular weight of 300 to 950 (daltons) for inhibiting the membrane transport mediated by the "multidrug resistance-associated protein" (MRP protein).
14. Use according to claim 13, characterized in that the amphiphilic anions are conjugates of lipophilic compounds having anionic groups selected from carboxyl, glucuronic acid, glutathione S, sulfate and cysteinylglycine groups.
15. Use according to Claim 13 or 14, characterized in that substances structurally related to the leukotrienes C4, D4, and E4, respectively, are used as inhibitors of the MRP protein.
16. Use according to any one of Claims 13 to 15, characterized in that cysteinyl-leukotriene receptor antagonists and compounds structurally related thereto are used as inhibitors of the MRP protein.
-80-
17. Use according to any one of Claims 13 to 16, characterized in that the inhibitor is employed in a concentration of 0.5 to 50 mg/kg body weight of the patient.
18. Use according to any one of Claims 13 to 16, characterized in that the concentration of the inhibitor is 0.1 to 10 micromolar at the site of action.
19. Test kit for measuring the inhibition of the MRP protein, containing membrane vesicles, ATP and radioactively labeled leukotrienes C4, D4 and/or E4 or fluorescent structural analogs of leukotriene C4, D4 and/or E4
20. A method of reversing MRP-mediated multiple drug resistance comprising administering an effective amount of a MRP reversal agent.
21. A method of reversing MRP-mediated multiple drug resistance comprising administering an effective amount of a compound of the formula:
Y is hydrogen or halo;
R2 is hydrogen, -OH, or -OCH3;
R3 is C1-C6 alkyl;
R4 is hydrogen, -OH, or -OCH3;
-81-
STATEMENT UNDER ARTICLE 19m
The International Search Report for the captioned application was mailed 11 Nfarch 1996. In accordance with Article 19 of the Patent Cooperation Treaty, applicants submit herewith replacement sheets (pages 74 and 75) for pages 74 and 75 of the International Application as originally filed.
The claims have been amended to correct obvious errors in the claim dependencies of claims 16, 17 and 18. Applicants respectfully request entry of the substitute sheets for pages 74 and 75 of the International Application as originally filed.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8508977A JPH10505348A (en) | 1994-08-31 | 1995-08-31 | Methods for identifying and treating resistant tumors |
| EP95932371A EP0777472A2 (en) | 1994-08-31 | 1995-08-31 | Methods for identifying and treating resistant tumors |
| AU35434/95A AU3543495A (en) | 1994-08-31 | 1995-08-31 | Methods for identifying and treating resistant tumors |
| US08/793,659 US6235785B1 (en) | 1994-08-31 | 1995-08-31 | Methods for identifying and treating resistant tumors |
| US09/836,429 US6673813B2 (en) | 1994-08-31 | 2001-04-17 | Methods for identifying and treating resistant tumors |
| US09/836,567 US20020013370A1 (en) | 1994-08-31 | 2001-04-17 | Methods for identifying and treating resistant tumors |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/298,644 US5543428A (en) | 1994-08-31 | 1994-08-31 | Method for treating resistant tumors |
| US08/298,644 | 1994-08-31 | ||
| DEP4432563.0 | 1994-09-13 | ||
| DE19944432563 DE4432563C2 (en) | 1994-09-13 | 1994-09-13 | Use of amphiphilic anions to reduce cytostatics resistance by inhibiting the membrane transport mediated by the MRP protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/793,659 Continuation-In-Part US6235785B1 (en) | 1994-08-31 | 1995-08-31 | Methods for identifying and treating resistant tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1996006604A2 WO1996006604A2 (en) | 1996-03-07 |
| WO1996006604A3 WO1996006604A3 (en) | 1996-08-01 |
| WO1996006604B1 true WO1996006604B1 (en) | 1996-09-12 |
Family
ID=25940080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1995/011125 WO1996006604A2 (en) | 1994-08-31 | 1995-08-31 | Methods for identifying and treating resistant tumors |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US6235785B1 (en) |
| EP (2) | EP0777472A2 (en) |
| JP (1) | JPH10505348A (en) |
| AU (1) | AU3543495A (en) |
| CA (1) | CA2198752A1 (en) |
| WO (1) | WO1996006604A2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3543495A (en) * | 1994-08-31 | 1996-03-22 | Deutsches Krebsforschungszentrum | Methods for identifying and treating resistant tumors |
| EP1115427B1 (en) * | 1998-09-25 | 2003-12-03 | Horst Lindhofer | Time-staggered utilization of tumor cells in combination with intact antibodies for immunization |
| WO2001034197A2 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| EP1326605A4 (en) * | 2000-05-09 | 2004-03-17 | Univ Creighton | USE OF INHIBITORS OF THE BINDING OF LEUKOTRIEN B4 TO LEUKOTRIEN B4 RECEPTOR TO INHIBIT PROLIFERATION AND INDUCTION OF APOPTOSE IN CANCER CELLS |
| AU9287401A (en) | 2000-09-27 | 2002-04-08 | Merck & Co Inc | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| AU2002248221B2 (en) | 2000-10-31 | 2006-08-17 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| HUP0303175A2 (en) * | 2001-02-20 | 2003-12-29 | Bristol-Myers Squibb Co. | Use of epothlone derivatives for preparation of pharmaceutical composition suitable for treatment of refractory tumors |
| WO2016149126A1 (en) | 2015-03-13 | 2016-09-22 | The Board Of Trustees Of The Leland Stanford Junior University | Ltb4 inhibition to prevent and treat human lymphedema |
| US10107437B2 (en) * | 2015-09-15 | 2018-10-23 | Mustang Sampling Llc | Tooling friendly adapter for insertion probe access |
| WO2017095724A1 (en) | 2015-11-30 | 2017-06-08 | Merck Sharp & Dohme Corp. | Aryl sulfonamides as blt1 antagonists |
| EP3383869B1 (en) | 2015-11-30 | 2023-06-28 | Merck Sharp & Dohme LLC | Aryl sulfonamides as blt1 antagonists |
| US10370368B2 (en) | 2015-11-30 | 2019-08-06 | Merck Sharp & Dohme Corp. | Aryl acylsulfonamides as BLT1 antagonists |
| US10336733B2 (en) | 2015-11-30 | 2019-07-02 | Merk Sharp & Dohme Corp. | Aryl acylsulfonamides as BLT1 antagonists |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211791A (en) | 1975-09-23 | 1980-07-08 | Beecham Group Limited | Indanediones |
| US4200577A (en) | 1975-09-23 | 1980-04-29 | Beecham Group Limited | Coumarin derivatives |
| US4889871A (en) | 1987-05-29 | 1989-12-26 | G. D. Searle & Co. | Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives |
| US5216024A (en) | 1987-07-28 | 1993-06-01 | Baylor College Of Medicine | Cell growth inhibitors and methods of treating cancer and cell proliferative diseases |
| US5216172A (en) | 1988-02-24 | 1993-06-01 | Ajinomoto Co., Inc. | 1,4-dihydropyridine-4-aryl-2,6-dimethyl-3,5-dicarboxylates useful as agents against drug resistant tumor cells |
| JPH02218654A (en) * | 1988-10-12 | 1990-08-31 | Ono Pharmaceut Co Ltd | Benzoic acid derivative, production thereof and drug containing the same |
| ZA925185B (en) | 1991-07-18 | 1993-04-29 | Hoffmann La Roche | Dithianes. |
| EP0544488B1 (en) * | 1991-11-25 | 1998-03-11 | Eli Lilly And Company | Substituted phenyl phenol leukotriene antagonists |
| PH30449A (en) | 1991-11-25 | 1997-05-28 | Lilly Co Eli | Substituted phenyl phenol leukotriene antagonists |
| CA2129143C (en) | 1992-02-06 | 1997-05-06 | Sai Prasad Sunkara | Reversal of multi-drug resistance by tetraarylethylenes |
| DE69325805T2 (en) | 1992-02-06 | 2000-03-16 | Merrell Pharmaceuticals Inc. | REVERSE OF MULTIPLE RESISTANCE TO MEDICINES BY TRIPHENYL-PIPERIDINE DERIVATIVES |
| WO1994006938A1 (en) | 1992-09-17 | 1994-03-31 | The Board Of Trustees Of The University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
| IL107462A0 (en) * | 1992-11-05 | 1994-02-27 | Lilly Co Eli | Drug resistance-conferring protein, antibodies reactive therewith and utilities thereof |
| US5324743A (en) * | 1992-12-10 | 1994-06-28 | Eli Lilly And Company | Leukotriene B4 antagonists |
| US5643909A (en) | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
| US5387685A (en) | 1993-07-16 | 1995-02-07 | American Cyanamid Co | MDR reversal agents |
| HUT71237A (en) * | 1993-10-15 | 1995-11-28 | Lilly Co Eli | Pharmaceutical compositions for treating resistant neoplasms containing 2-phenyl-3-aroil-benzotiophene derivatives and process for their preparation |
| US5543428A (en) | 1994-08-31 | 1996-08-06 | Eli Lilly And Company | Method for treating resistant tumors |
| AU3543495A (en) * | 1994-08-31 | 1996-03-22 | Deutsches Krebsforschungszentrum | Methods for identifying and treating resistant tumors |
-
1995
- 1995-08-31 AU AU35434/95A patent/AU3543495A/en not_active Abandoned
- 1995-08-31 EP EP95932371A patent/EP0777472A2/en not_active Withdrawn
- 1995-08-31 CA CA002198752A patent/CA2198752A1/en not_active Abandoned
- 1995-08-31 US US08/793,659 patent/US6235785B1/en not_active Expired - Fee Related
- 1995-08-31 WO PCT/US1995/011125 patent/WO1996006604A2/en not_active Application Discontinuation
- 1995-08-31 EP EP01103130A patent/EP1129707A3/en not_active Withdrawn
- 1995-08-31 JP JP8508977A patent/JPH10505348A/en not_active Ceased
-
2001
- 2001-04-17 US US09/836,567 patent/US20020013370A1/en not_active Abandoned
- 2001-04-17 US US09/836,429 patent/US6673813B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1996006604B1 (en) | Methods for identifying and treating resistant tumors | |
| Watson | Antidepressant drugs as adjuvant analgesics | |
| Ross et al. | Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer | |
| US5166207A (en) | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders | |
| KR960008234B1 (en) | Composition for reducing neurotoxic injury | |
| Jordan et al. | Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro. | |
| US20020128264A1 (en) | Methods for treatment of conditions affected by activity of multidrug transporters | |
| KR100291882B1 (en) | (1S, 2S) -1- (4-hydroxyphenyl) -2- (4-hydroxy-4-phenylpiperidin-1-yl) -1-propanolmethanesulfonate trihydrate | |
| US6124299A (en) | Calcitonin mimetics | |
| ATE213727T1 (en) | IN POSITION 3 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCIN AGONISTS AND/OR ANTAGONISTS | |
| BRPI0212346B1 (en) | COMPOUNDS DERIVED FROM BENZOTIADIAZEPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF WITH INHIBITING EFFECTS ON THE TRANSPORTATION OF ILEAL BILE ACID, PROCESS FOR THE PREPARATION OF THE SAME, USE THEREOF, AND, PHARMACEUTICAL COMPOSITION. | |
| KR960037675A (en) | Benzonitrile and benzofluoride | |
| JP2002114680A (en) | Antifungal agent | |
| MA27197A1 (en) | SALTS OF TOLTERODINE | |
| JP2968623B2 (en) | Novel derivatives of endogenous mediators, their salts, preparation methods, applications and compositions containing them | |
| CA2465886A1 (en) | Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells | |
| KR920008066A (en) | Amino acid derivatives | |
| Goss et al. | Haloperidol treatment increases D2 dopamine receptor protein independently of RNA levels in mice | |
| US8501752B2 (en) | Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines | |
| AU731125B2 (en) | Method for inducing death of neoplastic cells using piperazine oxirane derivatives | |
| Alvarado et al. | Effects of serotonin uptake blockers and of 5-hydroxytryptophan on the voluntary consumption of ethanol, water and solid food by UChA and UChB rats | |
| Hwang et al. | Interactions of sterols with antiestrogen-binding sites: structural requirements for high-affinity binding. | |
| Nauta et al. | Structure-activity relationships of H1-receptor antagonists | |
| AU672234B2 (en) | Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors | |
| Blanton et al. | Examining the noncompetitive antagonist-binding site in the ion channel of the nicotinic acetylcholine receptor in the resting state |